Literature DB >> 17279237

Amyotrophic lateral sclerosis: update for family physicians.

Christen L Shoesmith1, Michael J Strong.   

Abstract

OBJECTIVE: To discuss the epidemiology, pathogenesis, diagnosis, expected course, prognosis, and treatment of amyotrophic lateral sclerosis (ALS), a degenerative disorder of the nervous system associated with progressive weakness. QUALITY OF EVIDENCE: PubMed and the Cochrane Database of Systematic Reviews were searched using the MeSH headings "amyotrophic lateral sclerosis," "therapy," "epidemiology," and "etiology." Articles containing the best available evidence were reviewed. Most provided level II and III evidence. There were some level I drug trials. MAIN MESSAGE: Amyotrophic lateral sclerosis is associated with progressive dysarthria, dysphagia, and weakness in the extremities. Diagnosis is based on physical examination, electrophysiology, and excluding other confounding conditions. There is no cure for this devastating disorder. Certain treatments, however, can improve survival and quality of life.
CONCLUSION: Because ALS is a complex disease, care of ALS patients is best provided at multidisciplinary clinics that specialize in managing patients with this disorder.

Entities:  

Mesh:

Year:  2006        PMID: 17279237      PMCID: PMC1783756     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  50 in total

1.  A survey of clinicians' practice in the symptomatic treatment of ALS.

Authors:  Dallas A Forshew; Mark B Bromberg
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2003-12

2.  Amyotrophic lateral sclerosis--a new role for old drugs.

Authors:  Robert H Brown
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

3.  Percutaneous gastrojejunostomy in amyotrophic lateral sclerosis.

Authors:  M J Strong; A Rowe; R N Rankin
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

4.  Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease?

Authors:  Stefano Belli; Nicola Vanacore
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

5.  [The effect of amitriptyline on the pathological crying and other pseudobulbar signs].

Authors:  A Szczudlik; A Słowik; B Tomik
Journal:  Neurol Neurochir Pol       Date:  1995 Sep-Oct       Impact factor: 1.621

6.  A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps.

Authors:  P Khajehdehi; M Mojerlou; S Behzadi; G A Rais-Jalali
Journal:  Nephrol Dial Transplant       Date:  2001-07       Impact factor: 5.992

7.  A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients.

Authors:  C E Jackson; J Rosenfeld; D H Moore; W W Bryan; R J Barohn; M Wrench; D Myers; L Heberlin; R King; J Smith; D Gelinas; R G Miller
Journal:  J Neurol Sci       Date:  2001-10-15       Impact factor: 3.181

8.  Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis.

Authors:  Jean-Claude Desport; Tarek Mabrouk; Philippe Bouillet; Abuyaba Perna; Pierre-Marie Preux; Philippe Couratier
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2005-06

9.  Transdermal scopolamine for reduction of drooling in developmentally delayed children.

Authors:  D W Lewis; C Fontana; L K Mehallick; Y Everett
Journal:  Dev Med Child Neurol       Date:  1994-06       Impact factor: 5.449

10.  Treatment of pathologic laughing and weeping with amitriptyline.

Authors:  R B Schiffer; R M Herndon; R A Rudick
Journal:  N Engl J Med       Date:  1985-06-06       Impact factor: 91.245

View more
  6 in total

1.  Teamwork.

Authors:  Paul Bonisteel
Journal:  Can Fam Physician       Date:  2007-03       Impact factor: 3.275

2.  The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis.

Authors:  Frank O Johnson; William D Atchison
Journal:  Neurotoxicology       Date:  2009-07-24       Impact factor: 4.294

3.  Amyotrophic lateral sclerosis presenting as upper limb weakness in a 35 year old female: a case report.

Authors:  Leif A Sigurdson
Journal:  J Can Chiropr Assoc       Date:  2011-09

4.  Case-control study of occupational exposure to electric shocks and magnetic fields and mortality from amyotrophic lateral sclerosis in the US, 1991-1999.

Authors:  Ximena Vergara; Gabor Mezei; Leeka Kheifets
Journal:  J Expo Sci Environ Epidemiol       Date:  2014-06-11       Impact factor: 5.563

5.  Humoral factors in ALS patients during disease progression.

Authors:  Jared Ehrhart; Adam J Smith; Nicole Kuzmin-Nichols; Theresa A Zesiewicz; Israt Jahan; R Douglas Shytle; Seol-Hee Kim; Cyndy D Sanberg; Tuan H Vu; Clifton L Gooch; Paul R Sanberg; Svitlana Garbuzova-Davis
Journal:  J Neuroinflammation       Date:  2015-06-28       Impact factor: 8.322

6.  Medication use and risk of amyotrophic lateral sclerosis-a systematic review.

Authors:  Can Cui; Jiangwei Sun; Kyla A McKay; Caroline Ingre; Fang Fang
Journal:  BMC Med       Date:  2022-08-05       Impact factor: 11.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.